Clinical trial
A Phase II Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
NCT00055523 is registered in ClinicalTrials.gov with Abbott as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
- Lead sponsor
- Abbott
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2002
- Completion date
- Not reported
- Enrollment
- 300
- Sites
- 43
Conditions
As the registry lists them; a condition with its own page is linked.
crohn's disease